Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
$13.08
-$0.23(-2.31%)
At close: 4:00 PM EST
$13.08
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)6.30M
Market Cap
$927.38M
Enterprise Value$373.42M
Total Cash (Recent Filing)$36.09M
Total Debt (Recent Filing)$191.61M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 03, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding70,900,460
10 Day Avg. Volume2,077,952
30 Day Avg. Volume6,302,146
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-3.15
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-35.25
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$43.67Price Target Upside233.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial BackingAnalyst notes that the upfront payment from a major partner provides non-dilutive capital to address debt and extend operational runway, improving the company's ability to fund launch and pipeline activities.
Label Breadth And SafetyAnalyst emphasizes that a broad approved label covering all TA-TMA patients together with a favorable safety profile and no black-box warning may enable broader clinical use compared with off-label options.
Regulatory ApprovalAnalyst highlights that FDA approval of Yartemlea as the first and only therapy for TA-TMA creates an exclusive commercial position that could drive meaningful adoption and revenue potential.
Bears Say
Market Access And AdministrationAnalyst cautions that inpatient initiation and reliance on hospital-based administration could complicate access and slow early uptake across transplant centers.
Regulatory And Clinical-data RiskAnalyst notes persistent regulatory skepticism stemming from limited open-label datasets and earlier complete response concerns, which increases the risk of future review challenges.
Valuation ExpectationsAnalyst warns that the stock's valuation already reflects substantial expected sales from Yartemlea, leaving limited upside if commercial performance falls short of forecasts.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.95 and its highest was $17.65 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $927.38M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Mar 03, 2026 which is in 46 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.447 by -$0.023.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.57.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 70,900,460 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.447. Following the earnings report the stock price went up 25.318%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.67 (233.84% Upside)
$43.67 (233.84% Upside)
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $750.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 49.1%
Last 30 Days ▲ 49.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.73%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Omeros Corporation's earnings call highlighted a strategic partnership with Novo Nordisk, significant progress in regulatory approvals for Yartemlia, and improved financial positioning through debt repayment. Despite reporting a higher net loss and cash burn, the company's robust pipeline and upcoming milestones position it for potential future success.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$43.67
▲(233.84% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.32% Insiders
6.77% Mutual Funds
13.73% Other Institutional Investors
66.14% Public Companies and Individual Investors